Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX102 vaccine for influenza prevention in healthy adults
NCT00921947Phase 2Completed
- Sponsor
- VaxInnate Corporation
- Start
- Jun 2009
- Primary completion
- Jul 2009
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vax102 in influenza (2 arms), sponsored by VaxInnate Corporation. Primary endpoints: Number of Participants With Local and Systemic Symptoms Post Vaccination 1 (Day 0) and Number of Participants With Local and Systemic Symptoms Post Vaccination 2 (Day 28) at 14 days. Started Jun 2009; status: completed.
02
Drugs
vax102
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00921947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921947.